Patrizio Mattei

Patrizio Mattei

Auto-generated profile, based on publicly available information

Patrizio Mattei

Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
CZClaudia Zampaloni
Claudia Zampaloni
PMPatrizio Mattei
Patrizio Mattei
KBKonrad Bleicher
Konrad Bleicher
LWLotte Winther
Lotte Winther
CTClaudia Thäte
Claudia Thäte
KBKenneth A. Bradley
Kenneth A. Bradley
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.

3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
KPKaranbir S. Pahil
Karanbir S. Pahil
MGMorgan S. A. Gilman
Morgan S. A. Gilman
VBVadim Baidin
Vadim Baidin
TCThomas Clairfeuille
Thomas Clairfeuille
PMPatrizio Mattei
Patrizio Mattei
DKDaniel Kahne
Daniel Kahne
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.

11 July 2024 in Nature
Verified
Journal Article
Open access
PDF file
CZClaudia Zampaloni
Claudia Zampaloni
PMPatrizio Mattei
Patrizio Mattei
KBKonrad Bleicher
Konrad Bleicher
LWLotte Winther
Lotte Winther
CTClaudia Thäte
Claudia Thäte
KBKenneth A. Bradley
Kenneth A. Bradley

10 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
KPKaranbir S. Pahil
Karanbir S. Pahil
MGMorgan S. A. Gilman
Morgan S. A. Gilman
VBVadim Baidin
Vadim Baidin
TCThomas Clairfeuille
Thomas Clairfeuille
PMPatrizio Mattei
Patrizio Mattei
DKDaniel Kahne
Daniel Kahne

11 July 2024 in Nature
Verified
Journal Article
Open access
PDF file
KPKaranbir S. Pahil
Karanbir S. Pahil
MGMorgan S. A. Gilman
Morgan S. A. Gilman
VBVadim Baidin
Vadim Baidin
TCThomas Clairfeuille
Thomas Clairfeuille
PMPatrizio Mattei
Patrizio Mattei
DKDaniel Kahne
Daniel Kahne